Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis

Stopped early · Phase 4

Conditions studied: Dermatitis Herpetiformis

In brief

The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for lesion reduction will be defined as statistically greater mean percent reductions at week six in the dapsone gel-treated extremity compared with the control extremity of each patient.

Key facts

Study ID
NCT01115244
Run by
Vanderbilt University Medical Center
People needed
1
Starts
2010-07-01
Expected to finish
2012-03-01
Last updated by the study team
2017-12-14

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.